BioBalance Corp. (BioBalance), a wholly owned subsidiary of New York Health Care, Inc. (OTCBB: BBAL), announced today that it has begun enrollment of a small-scale clinical trial of its proprietary biotherapeutic agent, Probactrix®, in the dietary management of patients with gastro-esophageal reflux disease, also known as GERD.
